Top

Published in:

01-05-2008 | ssat plenary presentation

Quality of Life in Pancreatic Cancer: Analysis by Stage and Treatment

Authors: Stefano Crippa, Ismael Domínguez, J. Ruben Rodríguez, Oswaldo Razo, Sarah P. Thayer, David P. Ryan, Andrew L. Warshaw, Carlos Fernández-del Castillo

Published in: Journal of Gastrointestinal Surgery | Issue 5/2008

Abstract

In pancreatic cancer patients, survival and palliation of symptoms should be balanced with social and functional impairment, and for this reason, health-related quality of life measurements could play an important role in the decision-making process. The aim of this work was to evaluate the quality of life and survival in 92 patients with different stages of pancreatic adenocarcinoma who underwent surgical and/or medical interventions. Patients were evaluated with the Functional Assessment of Cancer Therapy questionnaires at diagnosis and follow-up (3 and 6 months). At diagnosis, 28 patients (30.5%) had localized disease (group 1) and underwent surgical resection, 34 (37%) had locally advanced (group 2), and 30 (32.5%) metastatic disease (Group 3). Improvement in quality of life was found in group 1, while in group 3, it decreased at follow-up (p = 0.03). No changes in quality of life in group 2 were found. Chemotherapy/chemoradiation seems not to significantly modify quality of life in groups 2 and 3. Median survival time for the entire cohort was 9.8 months (range, 1–24). One-year survival was 74%, 30%, and 16% for groups 1, 2, and 3 respectively (p = 0.001). Pancreatic cancer prognosis is still dismal. In addition to long-term survival benefits, surgery impacts favorably quality of life.

Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ. Cancer Statistics, 2005 CA. Cancer J Clin 2005;55:10–30.CrossRef

Yeo CJ, Cameron JL, Lillemoe KD, Sohn TA, Campbell KA, Sauter PK, Coleman J, Abrams RA, Hruban RH. Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2: randomized controlled trial evaluating survival, morbidity and mortality. Ann Surg 2002;236:355–366.PubMedCrossRef

Ferrone CR, Finkelstein DM, Thayer SP, Muzikansky A, Fernandez-del Castillo C, Warshaw AL. Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol 2006;24:2897–2902.PubMedCrossRef

Sener SF, Fremgen A, Menck HR, Winchester DP. Pancreatic caner: a report of treatment and survival trends for 100,313 patients diagnosed from 1985–1995, using the national cancer database. J Am Coll Surg 1999;189:1–7.PubMedCrossRef

Talamonti MS, Small W, Mulcahy MF, Wayne JD, Attaluri V, Coletti LM, Zalupski MM, Hoffman JP, Freedman GM, Kinsella TJ, Philip PA, McGrinn CJ. A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma. Ann Surg Oncol 2006;13:150–158.PubMedCrossRef

Yip D, Karapetis C, Strickland A, Steer CB, Goldstein D. Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer. Cochrane Database Syst Rev 2006;19:CD00093.

Ko AH, Dito E, Schillinger B, Venook AP, Bergsland EK, Tempero MA. Phase III study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas. J Clin Oncol 2006;24:379–385.PubMedCrossRef

Lillemoe KD, Pitt HA. Palliation. Surgical and otherwise. Cancer 1996;78:605–614.PubMed

Lillemoe KD, Cameron JL, Hardacre JM, Sohn TA, Sauter PK, Coleman J, Pitt HA, Yeo CJ. Is prophylactic gastrojejunostomy indicated for unresectable periampullary cancer? A prospective randomized trial. Ann Surg 1999;230:322–328.PubMedCrossRef

10.

Mortenson MM, Ho HS, Bold RJ. An analysis of cost and clinical outcome in palliation for advanced pancreatic cancer. Am J Surg 2005;190:406–411.PubMedCrossRef

11.

Labori KJ, Hjermstad MJ, Wester T, Buanes T, Loge JH. Symptom profiles and palliative care in advanced pancreatic cancer: a prospective study. Support Care Cancer 2006;14:1126–1133.PubMedCrossRef

12.

Artifon EL, Sakai P, Cunha JE, Dupont A, Filho FM, Hondo FY, Ishioka S, Raju GS. Surgery or endoscopy for palliation of biliary obstruction due to metastatic pancreatic cancer. Am J Gastroenterol 2006;101:2031–2037.PubMedCrossRef

13.

Maire F, Hammel P, Ponsot P, Aubert A, O’Toole D, Hentic O, Levy P, Ruszniewski P. Long-term outcome of biliary and duodenal stents in palliative treatment of patients with unresectable adenocarcinoma of the head of the pancreas. Am J Gastroenterol 2006;101:735–742.PubMedCrossRef

14.

Yan BM, Myers RP. Neurolytic celiac plexus block for pain control in unresectable pancreatic cancer. Am J Gastroenterol 2007;102:430–438.PubMedCrossRef

15.

Lillemoe KD, Cameron JL, Kaufman HS, Yeo CJ, Pitt HA, Sauter PK. Chemical splanchnicectomy in patients with unresectable pancreatic cancer. A prospective randomized trial. Ann Surg 1993;217:447–455.PubMedCrossRef

16.

Kuhlmann KF, de Castro SM, Wesseling JG, ten Kate FJ, Offerhaus GJ, Busch OR, van Gulik TM, Obertop H, Gouma DJ. Surgical treatment of pancreatic adenocarcinoma; actual survival and prognostic factors in 343 patients. Eur J Cancer 2004;40:549–558.PubMedCrossRef

17.

Velanovich V. Using quality-of-life measurements in clinical practice. Surgery 2007;141:127–133.PubMedCrossRef

18.

Huang JJ, Yeo CJ, Sohn TA, Lillemoe KD, Sauter PK, Coleman J, Hruban RH, Cameron JL. Quality of life and outcomes after pancreaticoduodenectomy. Ann Surg 2000;231:890–898.PubMedCrossRef

19.

Velanovich V. Using quality-of-life instruments to assess surgical outcomes. Surgery 1999;126:1–4.PubMedCrossRef

20.

Testa MA, Simonson D. Assessment of quality of life outcomes. N Engl J Med 1996;334:835–840.PubMedCrossRef

21.

Nieveen van Dijkum EJ, Kuhlmann KF, Terwee CB, Obertop H, de Haes JC, Gouma DJ. Quality of life after curative or palliative surgical treatment of pancreatic and periampullary carcinoma. Br J Surg 2005;92:471–477.PubMedCrossRef

22.

Billings BJ, Christein JD, Harmsen WS, Harrington JR, Chari ST, Que FG, Farnell MB, Nagorney DM, Sarr MG. Quality-of-life after total pancreatectomy: is it really that bad on long-term follow-up? J Gastrointest Surg 2005;9:1059–1066.PubMedCrossRef

23.

Nguyen TC, Sohn TA, Cameron JL, Lillemoe KD, Campbell KA, Coleman J, Sauter K, Abrams RA, Hruban RH, Yeo CJ. Standard vs. radical pancreaticoduodenectomy for periampullary adenocarcinoma: a prospective, randomized trial evaluating quality of life in pancreaticoduodenectomy survivors. J Gastrointest Surg 2003;7:1–9.PubMedCrossRef

24.

Farnell MB, Pearson RK, Sarr MG, DiMagno EP, Burgart LJ, Dahl TR, Foster N, Sargent DJ, Pancreas Cancer Working Group. A prospective randomized trial comparing standard pancreaticoduodenectomy with pancreaticoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinoma. Surgery 2005;138:618–628.PubMedCrossRef

25.

Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J. The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol 1993;11:570–579.PubMed

26.

Heffernan N, Cella DF, Webster K, Odom L, Martone M, Passik S, Bookbinder M, Fong Y, Jarnagin W, Blumgart L. Measuring health-related quality of life in patients with hepatobiliary cancers: the functional assessment of cancer therapy—hepatobiliary questionnaire. J Clin Oncol 2002;20:2229–2239.PubMedCrossRef

27.

Steel JL, Eton DT, Cella D, Olek MC, Carr BI. Clinically meaningful differences in health-related quality of life in patients diagnosed with hepatobiliary carcinoma. Ann Oncol 2006;17:304–312.PubMedCrossRef

28.

Brożek JL, Guyatt HG, Schünemann HJ. How a well-grounded minimal important difference can enhance transparency of labeling claims and improve interpretation of a patient reported outcome measure. Health Qual Life Outcomes 2006;4:1–7.CrossRef

29.

Morrow M, Hilaris B, Brennan MF. Comparison of conventional surgical resection, radioactive implantation, and bypass procedure for exocrine carcinoma of the pancreas 1975–1980. Ann Surg 1984;199:1–5.PubMedCrossRef

30.

Trede M, Schwall G, Saeger HD. Survival after pancreaticoduodenectomy: 118 consecutive resections without mortality. Ann Surg 1990;211:430–438.CrossRef

31.

Yeo CJ, Cameron JL, Sohn TA, Lillemoe KD, Pitt HA, Talamini MA, Hruban RH, Ord SE, Sauter PK, Coleman J, Zahurak ML, Grochow LB, Abrams RA. Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, outcomes. Ann Surg 1997;226:248–260.PubMedCrossRef

32.

Warshaw AL, Fernandez-del Castillo C. Pancreatic carcinoma. N Engl J Med 1992;326:455–465.PubMedCrossRef

33.

Nitecki SS, Sarr MG, Colby TV, van Heerden JA. Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving? Ann Surg 1995;221:59–66.PubMedCrossRef

34.

Sohn TA, Yeo CJ, Cameron JL, Koniaris L, Kaushal S, Abrams RA, Sauter PK, Coleman J, Hruban RH, Lillemoe KD. Resected adenocarcinoma of the pancreas—616 patients: results, outcomes, and prognostic indicators. J Gastroint Surger 2000;4:567–579.CrossRef

35.

Riall TS, Nealon WH, Goodwin JS, Zhang D, Kuo YF, Townsend CM Jr, Freeman JL. Pancreatic cancer in the general population: improvements in survival over the last decade. J Gastrointest Surg 2006;10:1212–1224.PubMedCrossRef

36.

Masucco P, Capussotti L, Magnino A, Sperti E, Gatti M, Muratore A, Sgotto E, Gabriele P, Aglietta M. Pancreatic resections after chemoradiotherapy for locally advanced ductal adenocarcinoma: analysis of perioperative outcome and survival. Ann Surg Oncol 2006;13:1201–1208.CrossRef

37.

Schniewind B, Bestmann B, Henne-Bruns D, Faendrich F, Kremer B, Kuechler T. Quality of life after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head. Br J Surg 2006;93:1099–1107.PubMedCrossRef

38.

Revicki D. FDA draft guidance and health-outcomes research. Lancet 2007;369:540–542.PubMedCrossRef

39.

Holzner B, Bode RK, Hahn EA, Cella D, Kopp M, Sperner-Unterweger B, Kemmler G. Equating EORTC QLQ-C30 and FACT-G scores and its use in oncological research. Eur J Cancer 2006;42:3169–3177.PubMedCrossRef

40.

Wong GY, Schroeder DR, Carns PE, Wilson JL, Martin DP, Kinney MO, Mantilla CB, Warner DO. Effect of neurolytic celiac plexus block on pain relief, quality of life, and survival in patients with unresectable pancreatic cancer: a randomized controlled trial. JAMA 2004;291:1092–1099.PubMedCrossRef

Title: Quality of Life in Pancreatic Cancer: Analysis by Stage and Treatment
Authors: Stefano Crippa
Ismael Domínguez
J. Ruben Rodríguez
Oswaldo Razo
Sarah P. Thayer
David P. Ryan
Andrew L. Warshaw
Carlos Fernández-del Castillo
Publication date: 01-05-2008
Publisher: Springer-Verlag
Published in: Journal of Gastrointestinal Surgery / Issue 5/2008
Print ISSN: 1091-255X
Electronic ISSN: 1873-4626
DOI: https://doi.org/10.1007/s11605-007-0391-9

At a glance: The STEP trials

Springer Medicine

Quality of Life in Pancreatic Cancer: Analysis by Stage and Treatment

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2008

Treatment of Hemorrhoids in Day Surgery: Stapled Hemorrhoidopexy vs Milligan–Morgan Hemorrhoidectomy

Clinical Analysis of Ectopic Pancreas with Endoscopic Ultrasonography: An Experience in a Medical Center

Liver Regeneration and Tumor Stimulation—A Review of Cytokine and Angiogenic Factors

Conservative Management of Adhesive Small Bowel Obstructions in Patients Previously Operated on for Primary Colorectal Cancer

Efficacy of Laparoscopic Mesh-Augmented Hiatoplasty in GERD and Symptomatic Hiatal Hernia. Study Using Combined Impedance-pH Monitoring

Operative Mortality After Hepatic Resection: Are Literature-Based Rates Broadly Applicable?